TR201910117T4 - OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları. - Google Patents
OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları. Download PDFInfo
- Publication number
- TR201910117T4 TR201910117T4 TR2019/10117T TR201910117T TR201910117T4 TR 201910117 T4 TR201910117 T4 TR 201910117T4 TR 2019/10117 T TR2019/10117 T TR 2019/10117T TR 201910117 T TR201910117 T TR 201910117T TR 201910117 T4 TR201910117 T4 TR 201910117T4
- Authority
- TR
- Turkey
- Prior art keywords
- ospa
- polypeptide
- nucleic acid
- related methods
- mutant fragments
- Prior art date
Links
- 108700006640 OspA Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 206010061591 Borrelia infection Diseases 0.000 abstract 2
- 101710105714 Outer surface protein A Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920002101 Chitin Polymers 0.000 abstract 1
- 210000004900 c-terminal fragment Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Bu buluş, Borrelia enfeksiyonunun önlenmesi ve tedavisi için bileşimler ve bunların yöntemlerde kullanımları ile ilgilidir. Özellikle, bu buluş; bir dış yüzey proteini A'nın (OspA) bir hibrit C-terminal fragmanını içeren bir polipeptit, aynısını kodlayan bir nükleik asit, nükleik asit içeren bir konakçı hücre, polipeptit ve polipeptit ve/veya nükleik asit içeren bir farmasötik bileşime (özellikle bir ilaç olarak ya da bir Borrelia enfeksiyonunun tedavi ya da önlenme yönteminde kullanılması için) ilaveten farmasötik bileşim ve bir ikinci bileşimi içeren bir kitin üretimi için bir yöntem ile ilgilidir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14150682 | 2014-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201910117T4 true TR201910117T4 (tr) | 2019-07-22 |
Family
ID=49917594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2019/10117T TR201910117T4 (tr) | 2014-01-09 | 2015-01-09 | OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları. |
Country Status (24)
Country | Link |
---|---|
US (4) | US9975927B2 (tr) |
EP (2) | EP3092246B1 (tr) |
JP (1) | JP6505110B2 (tr) |
KR (1) | KR102460165B1 (tr) |
CN (1) | CN105980398B (tr) |
AU (1) | AU2015205520B2 (tr) |
BR (2) | BR122023024315A2 (tr) |
CA (1) | CA2931110A1 (tr) |
CY (1) | CY1121734T1 (tr) |
DK (1) | DK3092246T3 (tr) |
EA (1) | EA034554B1 (tr) |
ES (1) | ES2740985T3 (tr) |
HR (1) | HRP20191086T1 (tr) |
HU (1) | HUE043779T2 (tr) |
LT (1) | LT3092246T (tr) |
MX (1) | MX369195B (tr) |
NZ (1) | NZ721015A (tr) |
PL (1) | PL3092246T3 (tr) |
PT (1) | PT3092246T (tr) |
RS (1) | RS59075B1 (tr) |
SI (1) | SI3092246T1 (tr) |
TR (1) | TR201910117T4 (tr) |
WO (1) | WO2015104396A1 (tr) |
ZA (1) | ZA201602690B (tr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
KR102460165B1 (ko) | 2014-01-09 | 2022-10-28 | 발네바 오스트리아 게엠베하 | Ospa의 돌연변이 단편 및 이와 관련된 방법 및 용도 |
WO2018189372A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
CN110483624B (zh) * | 2019-08-22 | 2021-02-09 | 中国疾病预防控制中心传染病预防控制所 | 伽氏疏螺旋体OspA蛋白C端肽段及其应用 |
US20240026412A1 (en) * | 2020-04-09 | 2024-01-25 | Valneva Austria Gmbh | Improved methods of producing a lipidated protein |
JP2023522170A (ja) | 2020-04-09 | 2023-05-29 | バルネバ オーストリア ゲーエムベーハ― | 医学的使用のための3つのOspA融合タンパク質を含む組成物 |
WO2023212520A1 (en) | 2022-04-25 | 2023-11-02 | Pfizer Inc. | Compositions and methods for eliciting an immune response protective against lyme disease |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248562B1 (en) * | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
WO2002016421A2 (en) * | 2000-08-18 | 2002-02-28 | Research Foundation Of The State University Of New York | Altered ospa of borrelia burgdorferi |
UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
CN101516905A (zh) | 2006-09-15 | 2009-08-26 | 英特塞尔股份公司 | 疏螺旋体属抗原 |
LT2484375T (lt) | 2006-09-26 | 2018-07-10 | Infectious Disease Research Institute | Vakcinos kompozicija, turinti sintetinio adjuvanto |
EP3705133A3 (en) * | 2010-05-14 | 2021-01-06 | Baxalta Incorporated | Ospa chimeras and use thereof in vaccines |
TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
US8986704B2 (en) * | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
KR102460165B1 (ko) | 2014-01-09 | 2022-10-28 | 발네바 오스트리아 게엠베하 | Ospa의 돌연변이 단편 및 이와 관련된 방법 및 용도 |
CZ2014320A3 (cs) | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
WO2018189372A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
-
2015
- 2015-01-09 KR KR1020167015981A patent/KR102460165B1/ko active IP Right Grant
- 2015-01-09 RS RS20190970A patent/RS59075B1/sr unknown
- 2015-01-09 HU HUE15703228A patent/HUE043779T2/hu unknown
- 2015-01-09 WO PCT/EP2015/050365 patent/WO2015104396A1/en active Application Filing
- 2015-01-09 BR BR122023024315-3A patent/BR122023024315A2/pt unknown
- 2015-01-09 SI SI201530777T patent/SI3092246T1/sl unknown
- 2015-01-09 EA EA201691095A patent/EA034554B1/ru unknown
- 2015-01-09 ES ES15703228T patent/ES2740985T3/es active Active
- 2015-01-09 EP EP15703228.5A patent/EP3092246B1/en active Active
- 2015-01-09 NZ NZ721015A patent/NZ721015A/en unknown
- 2015-01-09 PT PT15703228T patent/PT3092246T/pt unknown
- 2015-01-09 AU AU2015205520A patent/AU2015205520B2/en active Active
- 2015-01-09 BR BR112016015678A patent/BR112016015678B1/pt active IP Right Grant
- 2015-01-09 TR TR2019/10117T patent/TR201910117T4/tr unknown
- 2015-01-09 CN CN201580003319.2A patent/CN105980398B/zh active Active
- 2015-01-09 LT LTEP15703228.5T patent/LT3092246T/lt unknown
- 2015-01-09 PL PL15703228T patent/PL3092246T3/pl unknown
- 2015-01-09 MX MX2016008989A patent/MX369195B/es active IP Right Grant
- 2015-01-09 CA CA2931110A patent/CA2931110A1/en active Pending
- 2015-01-09 JP JP2016541706A patent/JP6505110B2/ja active Active
- 2015-01-09 US US15/110,151 patent/US9975927B2/en active Active
- 2015-01-09 EP EP19177679.8A patent/EP3564257A1/en active Pending
- 2015-01-09 DK DK15703228.5T patent/DK3092246T3/da active
-
2016
- 2016-04-19 ZA ZA2016/02690A patent/ZA201602690B/en unknown
-
2018
- 2018-04-04 US US15/944,835 patent/US10766931B2/en active Active
-
2019
- 2019-06-17 HR HRP20191086 patent/HRP20191086T1/hr unknown
- 2019-06-27 CY CY20191100676T patent/CY1121734T1/el unknown
-
2020
- 2020-08-11 US US16/990,023 patent/US11572392B2/en active Active
-
2023
- 2023-01-06 US US18/150,971 patent/US20230322869A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201910117T4 (tr) | OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları. | |
CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
PH12018500642A1 (en) | Anti-garp antibody | |
MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
PH12017501583A1 (en) | Novel proteins specific for cd137 | |
PH12019500596A1 (en) | Recombinant binding proteins and their use | |
CA2818969A1 (en) | Improved n-terminal capping modules for designed ankyrin repeat proteins | |
MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
TR201901077T4 (tr) | Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar | |
MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MY167232A (en) | Polypeptides binding to human complement c5 | |
MX2022007122A (es) | Dominios de repetición de anquirina diseñados con residuos de superficie alterados. | |
EA201690159A1 (ru) | Способы и композиции для лечения рака | |
PH12020550986A1 (en) | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
MX360085B (es) | Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. | |
MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
EA201790349A1 (ru) | Производные 6-алкинил-пиридина в качестве миметиков белка smac | |
PH12018501114A1 (en) | Polypeptides inhibiting cd40l | |
AU2018277310A1 (en) | Aggrecan binding immunoglobulins | |
BR112017006969A2 (pt) | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno | |
UA114298C2 (uk) | Пептид торк та вакцина, що його містить | |
MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. |